These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17654442)

  • 1. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus.
    Hamilton SJ; Chew GT; Watts GF
    Diab Vasc Dis Res; 2007 Jun; 4(2):89-102. PubMed ID: 17654442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelial dysfunction and cardiovascular disease--the lull before the storm.
    Marx N; Grant PJ
    Diab Vasc Dis Res; 2007 Jun; 4(2):82-3. PubMed ID: 17654440
    [No Abstract]   [Full Text] [Related]  

  • 3. Does drug therapy reverse endothelial progenitor cell dysfunction in diabetes?
    Desouza CV
    J Diabetes Complications; 2013; 27(5):519-25. PubMed ID: 23809765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The endothelium and vascular inflammation in diabetes.
    Hartge MM; Unger T; Kintscher U
    Diab Vasc Dis Res; 2007 Jun; 4(2):84-8. PubMed ID: 17654441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5' adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway.
    Cheang WS; Tian XY; Wong WT; Lau CW; Lee SS; Chen ZY; Yao X; Wang N; Huang Y
    Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):830-6. PubMed ID: 24482374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does reversal of oxidative stress and inflammation provide vascular protection?
    Koh KK; Oh PC; Quon MJ
    Cardiovasc Res; 2009 Mar; 81(4):649-59. PubMed ID: 19098298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.
    Woodman RJ; Chew GT; Watts GF
    Drugs; 2005; 65(1):31-74. PubMed ID: 15610050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial dysfunction: clinical strategies for treating oxidant stress.
    Fenster BE; Tsao PS; Rockson SG
    Am Heart J; 2003 Aug; 146(2):218-26. PubMed ID: 12891188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial dysfunction and hypertension in diabetes mellitus.
    Dandona P; Chaudhuri A; Aljada A
    Med Clin North Am; 2004 Jul; 88(4):911-31, x-xi. PubMed ID: 15308385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the endothelium to prevent diabetes-related atherosclerosis.
    Kearney MT
    Diab Vasc Dis Res; 2010 Jul; 7(3):177. PubMed ID: 20699387
    [No Abstract]   [Full Text] [Related]  

  • 15. Resveratrol and endothelial function: A literature review.
    Parsamanesh N; Asghari A; Sardari S; Tasbandi A; Jamialahmadi T; Xu S; Sahebkar A
    Pharmacol Res; 2021 Aug; 170():105725. PubMed ID: 34119624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.
    Martens FM; Rabelink TJ; op 't Roodt J; de Koning EJ; Visseren FL
    Eur Heart J; 2006 Jul; 27(13):1605-9. PubMed ID: 16762982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance and the endothelium.
    Hsueh WA; Lyon CJ; Quiñones MJ
    Am J Med; 2004 Jul; 117(2):109-17. PubMed ID: 15234647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes and endothelial dysfunction: a clinical perspective.
    Calles-Escandon J; Cipolla M
    Endocr Rev; 2001 Feb; 22(1):36-52. PubMed ID: 11159815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?
    Pernow J; Jung C
    Cardiovasc Res; 2013 Jun; 98(3):334-43. PubMed ID: 23417041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme.
    Ruilope LM; Redón J; Schmieder R
    Vasc Health Risk Manag; 2007; 3(1):1-9. PubMed ID: 17583170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.